RVNC Revance Therapeutics, Inc.

19.85
+1  (3%)
Previous Close 19.35
Open 19.35
Price To book 3.13
Market Cap 581.98M
Shares 29,319,000
Volume 153,786
Short Ratio 27.60
Av. Daily Volume 181,333

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2H 2017.
RT002
Plantar fasciitis
Phase 3 endpoints not met June 2016
RT001 - REALISE 1
Lateral Canthal (Crow’s Feet) Lines
Phase 2 full data due 2Q 2017.
RT002
Cervical dystonia
Phase 3 completion of enrollment announced March 8, 2017. Data due 4Q 2017.
RT002 - SAKURA
Moderate to severe glabellar (frown) lines

Latest News

  1. Revance Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : RVNC-US : March 21, 2017
  2. REVANCE THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
  3. Revance Therapeutics, Inc. :RVNC-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017
  4. Revance Completes Enrollment in Phase 3 Pivotal Trials of RT002 Injectable for the Treatment of Glabellar (Frown) Lines
  5. REVANCE THERAPEUTICS, INC. Financials
  6. Revance Announces BELMONT Phase 2 Clinical Data to Be Presented at the 2017 American Academy of Dermatology (AAD) Annual Meeting
  7. REVANCE THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
  8. Edited Transcript of RVNC earnings conference call or presentation 27-Feb-17 9:30pm GMT
  9. Revance reports 4Q loss
  10. Revance reports 4Q loss
  11. REVANCE THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
  12. Revance Releases Fourth Quarter and Full Year 2016 Results
  13. Q4 2016 Revance Therapeutics Inc Earnings Release - After Market Close
  14. Revance to Participate in Upcoming Investor Conferences
  15. Revance Therapeutics to Release Fourth Quarter 2016 Financial Results Monday, February 27, 2017
  16. REVANCE THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
  17. Revance Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : RVNC-US : January 31, 2017
  18. BELMONT Phase 2 Clinical Data to be Presented at IMCAS World Congress 2017
  19. BELMONT Phase 2 Clinical Data to be Presented at IMCAS World Congress 2017
  20. Revance Presents Clinical Data for RT002 Injectable at TOXINS 2017